Hypera logo

Hypera(OTC) HYPMY

Market Cap$3.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-49%
5 Year+16%
1 Year+46%
1 Month+18%
$5.30
+4.95%
+0.25Today
Hypera last closing stock price
MetricPriceDate
Last closeUSD 5.302026-10-16
Hypera stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 5.302026-10-09
1 month+17.96%USD 4.492026-09-16
3 month+31.14%USD 4.042026-07-17
Year to date+32.53%USD 4.002025-12-31
1 year+45.7%USD 3.642025-10-16
3 year-8.61%USD 5.802023-10-17
5 year+16.31%USD 4.562021-10-15
Since inception-48.62%USD 10.312010-05-27

Hypera Financials at a Glance

Market Cap

$3.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

R$8.78B

Net Income (TTM)

R$1.74B

EPS (TTM)

$0.50

P/E Ratio

10.51

Dividend

$0.21

Beta (Volatility)

0.47 (Low)

Price

$5.30

Volume

45,763

Open

$5.03

Previous Close

$5.30

Daily Range

$4.96 - $5.36

52-Week Range

$3.75 - $5.77

Estimated Earnings Date

Nov 11, 2026

HYPMY News

View of Salvador City, Bahia, Brazil

Three Top Dividend Stocks in Brazil

Asit Sharma, CPAAug 24, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hypera

Hypera S.A. is a leading pharmaceutical company based in Brazil, specializing in a wide range of prescription medications and consumer health products. The company boasts a diverse portfolio that includes well-known brands and generic medicines, catering to various healthcare needs.

Products and Services
  • Prescription medications under various brand names
  • Dermo-cosmetic solutions through Mantecorp Skincare
  • Nutritional and vitamin supplements, including Tamarine and Vitasay
Growth Outlook
  • Revenue increased to BRL 2.34 billion in Q2 2026, up from BRL 1.98 billion in Q1 2026
  • Net income rose to BRL 490 million in Q2 2026, reflecting strong operational performance
  • Operating income margin improved to 28.6% in Q2 2026, indicating efficient cost management
Financial Highlights
  • Trailing twelve-month revenue of BRL 8.5 billion, showcasing consistent growth
  • Net profit margin of 20% for the latest quarter, demonstrating profitability
  • Dividend yield of 4.3% TTM, appealing for income-focused investors
Hypera S.A. has established itself as a significant player in the Brazilian pharmaceutical market, with a strong emphasis on innovation and quality. The company's diverse product offerings cater to a wide range of consumer needs, from prescription medications to over-the-counter health solutions. Recent financial performance indicates robust growth, with a notable increase in revenue and net income in the latest quarter. The improvement in operating income margin reflects effective cost management strategies, positioning the company favorably for future growth. Additionally, the attractive dividend yield may appeal to investors seeking income generation. Overall, Hypera S.A. presents a compelling opportunity for those interested in the healthcare sector.
AI Generated • Oct 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,564

CEO

Breno Toledo Pires de Oliveira, MBA

Website

www.hypera.com.br

Headquarters

São Paulo, SP 05676-120, BR

HYPMY Financials

Key Financial Metrics (TTM)

Gross Margin

58.79%

Operating Margin

28.17%

Net Income Margin

19.80%

Return on Equity

13.10%

Return on Capital

7.95%

Return on Assets

6.04%

Earnings Yield

9.51%

Dividend Yield

3.88%

Payout Ratio

42.97%

Stock Overview

Market Cap

$3.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

703.99M

Volume

45.76K

Avg. Volume

94.41K

Financials (TTM)

Gross Profit

R$5.32B

Operating Income

R$2.48B

EBITDA

R$2.93B

Operating Cash Flow

R$2.41B

Capital Expenditure

-R$507.37M

Free Cash Flow

R$1.90B

Cash & ST Invst.

R$1.58B

Total Debt

R$7.48B

Hypera Performance Analysis

Hypera annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31BRL 1,461,193,21232.8%
20232023-12-31BRL 1,584,554,0728.4%
20242024-12-31BRL 1,380,548,586-12.9%
20252025-12-31BRL 1,378,112,275-0.2%
Hypera sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.4%
Q42025-12-310.4%
Q12026-03-31-11.5%
Q22026-06-3018.0%
Hypera annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31BRL 0.5133.4%
20232023-12-31BRL 0.510.6%
20242024-12-31BRL 0.39-24.6%
20252025-12-31BRL 0.33-13.8%
Hypera sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.5%
Q42025-12-31-1.4%
Q12026-03-31-23.9%
Q22026-06-3029.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

R$2.34B

+8.5%

Gross Profit

R$1.44B

+11.5%

Gross Margin

61.78%

N/A

Market Cap

$3.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$353.20K

N/A

Employees

10,564

N/A

Net Income

R$490.24M

+14.9%

EBITDA

R$755.79M

-1.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

R$1.58B

+31.1%

Total Debt

R$7.48B

-15.6%

Accounts Receivable

R$1.71B

+7.4%

Inventory

R$1.93B

-8.6%

Long Term Debt

R$7.19B

-1.6%

Short Term Debt

R$294.35M

-81.1%

Return on Assets

6.04%

N/A

Return on Invested Capital

9.67%

N/A

Free Cash Flow

R$687.46M

+216.3%

Operating Cash Flow

R$819.20M

+85.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APNHYAspen Pharmacare Holdings Limited
$9.64+0.00%
HKMPYHikma Pharmaceuticals PLC
$44.41+0.02%
BHCBausch Health Companies Inc.
$6.30-0.16%
PRGOPerrigo Company plc
$16.63+0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About HYPMY

What is the current price of Hypera?

Hypera is trading at $5.30 per share.

What is the 52-week range for Hypera?

Over the past 52 weeks, Hypera has traded between $3.75 and $5.77.

How much debt does Hypera have?

As of the most recent reporting period, Hypera reported total debt of R$1.48B.

How much cash does Hypera have on hand?

Hypera reported R$304.97M in cash and cash equivalents in its most recent financial results.

What is Hypera’s dividend yield?

Hypera currently has a dividend yield of 3.88%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services